For the Inventor, By the Inventor

Enter assignee name

San Carlos, CA, United States of America

Deltagen, Inc.

USPTO Granted Patents = 14

% Expired Patents = 92.9

Forward Citations = 13

Loading Chart...

Loading Chart...

9 inventors (with patents filed for the assignee):

Keith D Allen (7 out of 10 patents)

Thomas J Brennan (3 out of 5 patents)

Michael W Leviten (2 out of 11 patents)

4. Christian W Siebel (1 out of 19 patents)

5. Mark R Moore (1 out of 47 patents)

6. Robert D Klein (1 out of 20 patents)

7. William Matthews (1 out of 12 patents)

8. Robert G Wisotzkey (1 out of 1 patent)

9. Catherine Guenther (1 out of 1 patent)

14 patents: Sort by Forward Citations

1. 7176346 - SLC19A2 amino acid transporter gene disruptions, and compositions and methods related thereto (2007-02-13),

2. 7164055 - HSPC150-like gene disruptions, compositions and methods related thereto (2007-01-16),

3. 7030291 - CYT28 serpentine receptor disruptions, compositions and methods relating thereto (2006-04-18),

4. 6943277 - Transgenic mice containing stefin homolog protease inhibitor gene disruptions (2005-09-13),

5. 6942995 - Methods of creating constructs useful for introducing sequences into embryonic stem cells (2005-09-13),

6. 6929909 - Gene targeting vectors comprising conditional positive selection markers (2005-08-16),

7. 6909031 - Transgenic mice containing glucagon receptor gene disruptions (2005-06-21),

8. 6858772 - Transgenic mice containing magnesium-dependent protein phosphatase gene disruptions (2005-02-22),

9. 6784335 - Transgenic mice containing BMP gene disruptions (2004-08-31),

10. 6765126 - Transgenic mice containing NPY6-R neuropeptide receptor gene disruptions (2004-07-20),

11. 6762342 - Transgenic mice containing intestinal alkaline phosphatase gene disruptions (2004-07-13),

12. 6730821 - Transgenic mice containing retina-specific nuclear receptor gene disruptions (2004-05-04),

13. 6717032 - Transgenic mice containing DEZ orphan receptor gene disruptions (2004-04-06),

14. 6653526 - Transgenic mice exhibiting increased susceptibility to seizures (2003-11-25),

Company Overview

Deltagen, Inc. is a biotechnology company based in San Carlos, California, specializing in the development of innovative solutions for drug discovery and development. The organization focuses on leveraging advanced genetic engineering techniques to create and utilize animal models that facilitate the understanding of human diseases and the identification of therapeutic targets. Deltagen's expertise lies in the integration of genomics and high-throughput screening technologies, positioning it as a key player in the biopharmaceutical landscape.

Profile summary synthesized from public USPTO records and patent filings.

Company Badge

USPTO Data Jan 1 1976 - Oct 20 2026

14 Patents

#29 in San Carlos, CA

#5,322 in California

#22,333 in US

#42,290 in the World

San Carlos, CA, United States of America

Deltagen, Inc.

Forward Citations = 13

9 inventors:

Keith D Allen (7 out of 10 patents)

Thomas J Brennan (3 out of 5 patents)

Michael W Leviten (2 out of 11 patents)

4. Christian W Siebel (1 out of 19 patents)

5. Mark R Moore (1 out of 47 patents)

IDiyas Innovation Intelligence. (2026). Company Patent Portfolio: Deltagen, Inc.. Retrieved from https://idiyas.com/company/deltagen

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]

Loading…